# Contact — NextGen Peptides

> Contact NextGen Peptides with corrections, citation issues, or research updates. We welcome substantive feedback on the literature summaries.

## Get in touch

NextGen Peptides is a small independent desk maintained to keep the incretin-class literature summaries accurate and current. The fastest way to reach us is via email.

## What we welcome

**Citation corrections.** If a specific number, hazard ratio, or study attribution is wrong — tell us, with the source. We will check it against the primary publication and correct or note it.

**New publications.** The Phase 3 retatrutide trials (TRIUMPH series) and tirzepatide cardiovascular-outcomes data will change the picture materially when they report. If you have a citation we have missed, we want to know.

**Structural feedback.** If a section is confusing, overstates certainty, or understates a safety signal — that is useful feedback too.

We do not respond to inquiries about sourcing any compound, to requests for medical advice, or to marketing messages.

## What we do not handle

This site does not sell products, provide referrals, or give medical or clinical guidance of any kind. Questions about whether a compound is appropriate for a specific person, how to use it, where to obtain it, or how to combine it with other medications are outside the scope of this desk entirely — those questions belong with a qualified healthcare provider.

For research-grade compound sourcing or clinical trial participation questions, consult ClinicalTrials.gov for active trial enrollment.

---

A literature digest of peer-reviewed incretin research — effect sizes reported as published, not as clinical guidance.